## **Core Concept**
Eculizumab is a monoclonal antibody that targets the complement component 5 (C5), a part of the complement system which plays a significant role in the innate immune response. By inhibiting C5, eculizumab prevents the formation of the membrane attack complex (MAC) and the pro-inflammatory mediators, anaphylatoxin C5a. This mechanism is crucial in treating conditions where complement-mediated hemolysis and inflammation are pathogenic.

## **Why the Correct Answer is Right**
Eculizumab is specifically used in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS). PNH is a rare, acquired, life-threatening disease of the blood characterized by the destruction of red blood cells (hemolysis), bone marrow failure, and the presence of blood clots (thrombosis). aHUS is a rare disease characterized by thrombosis in small blood vessels throughout the body, anemia, and kidney failure. In both conditions, the complement system is overactivated, leading to the destruction of red blood cells and other clinical manifestations. By blocking C5, eculizumab effectively reduces hemolysis, thrombosis, and organ damage in these diseases.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is not provided, but typically, incorrect options might include conditions not primarily associated with complement-mediated pathology, such as certain viral infections or autoimmune diseases not directly linked to C5 activation.
- **Option B:** Similarly, without the specific text, one might guess this could refer to a condition like Myasthenia Gravis, which, although autoimmune, does not primarily involve the complement system's dysregulation through C5.
- **Option C:** This could potentially refer to another condition; however, without specifics, it's hard to address directly. Conditions like systemic lupus erythematosus (SLE) involve the complement system but are not primarily treated with C5 inhibitors as first-line therapy.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that eculizumab increases the risk of infections, particularly with encapsulated bacteria like Neisseria species, because it inhibits the terminal complement pathway, which is important for clearing these pathogens. Therefore, vaccination against certain infections, such as meningococcal disease, is recommended before starting eculizumab.

## **Correct Answer:** D. Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS).